Ergoteles LLC Protagonist Therapeutics, Inc Transaction History

Ergoteles LLC

  • $68.2 Billion
  • Q3 2023

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$7.36 - $11.17 $48,060 - $72,940
-6,530 Reduced 22.11%
23,000 $250,000
Q3 2022

Nov 14, 2022
BUY
$7.86 - $11.71 $232,105 - $345,796
29,530 New
29,530 $249,000
Q1 2021

May 12, 2021
SELL
$19.02 - $31.15 $222,534 - $364,455
-11,700 Closed
0 $0
Q4 2020

Feb 11, 2021
BUY
$18.49 - $25.13 $216,332 - $294,021
11,700 New
11,700 $236,000

Others Institutions Holding PTGX

# of Institutions
248
Shares Held
56.7M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email